BACKGROUND: Long-acting beta-agonists may increase the risk for fatal and nonfatal asthma exacerbations. PURPOSE: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting beta-agonists. DATA SOURCES: English- and non-English-language searches of MEDLINE, EMBASE, and Cochrane databases; the U.S. Food and Drug Administration Web site; and references of selected reviews through December 2005. STUDY SELECTION: Randomized, placebo-controlled trials that lasted at least 3 months and evaluated long-acting beta-agonist use in patients with asthma. All trials allowed the use of as-needed short-acting beta-agonists. DATA EXTRACTION: Outcomes measured were Peto odds ratio (OR) and risk difference of severe exacerbations requiring hospitalization, life-threatening exacerbations requiring intubation and ventilation, and asthma-related deaths. The OR for asthma-related deaths was obtained from the Salmeterol Multi-center Asthma Research Trial (SMART). DATA SYNTHESIS: Pooled results from 19 trials with 33 826 participants found that long-acting beta-agonists increased exacerbations requiring hospitalization (OR, 2.6 [95% CI, 1.6 to 4.3]) and life-threatening exacerbations (OR, 1.8 [CI, 1.1 to 2.9]) compared with placebo. Hospitalizations were statistically significantly increased with salmeterol (OR, 1.7 [CI, 1.1 to 2.7]) and formoterol (OR, 3.2 [CI, 1.7 to 6.0]) and in children (OR, 3.9 [CI, 1.7 to 8.8]) and adults (OR, 2.0 [CI, 1.1 to 3.9]). The absolute increase in hospitalization was 0.7% (CI, 0.1% to 1.3%) over 6 months. The risk for asthma-related deaths was increased (OR, 3.5 [CI, 1.3 to 9.3]), with a pooled risk difference of 0.07% (CI, 0.01% to 0.1%). LIMITATIONS: The small number of deaths limited the reliability in assessing this risk, and 28 studies did not report information on the outcomes of interest. CONCLUSIONS: Long-acting beta-agonists have been shown to increase severe and life-threatening asthma exacerbations, as well as asthma-related deaths.
BACKGROUND: Long-acting beta-agonists may increase the risk for fatal and nonfatal asthma exacerbations. PURPOSE: To assess the risk for severe, life-threatening, or fatal asthma exacerbations associated with long-acting beta-agonists. DATA SOURCES: English- and non-English-language searches of MEDLINE, EMBASE, and Cochrane databases; the U.S. Food and Drug Administration Web site; and references of selected reviews through December 2005. STUDY SELECTION: Randomized, placebo-controlled trials that lasted at least 3 months and evaluated long-acting beta-agonist use in patients with asthma. All trials allowed the use of as-needed short-acting beta-agonists. DATA EXTRACTION: Outcomes measured were Peto odds ratio (OR) and risk difference of severe exacerbations requiring hospitalization, life-threatening exacerbations requiring intubation and ventilation, and asthma-related deaths. The OR for asthma-related deaths was obtained from the Salmeterol Multi-center Asthma Research Trial (SMART). DATA SYNTHESIS: Pooled results from 19 trials with 33 826 participants found that long-acting beta-agonists increased exacerbations requiring hospitalization (OR, 2.6 [95% CI, 1.6 to 4.3]) and life-threatening exacerbations (OR, 1.8 [CI, 1.1 to 2.9]) compared with placebo. Hospitalizations were statistically significantly increased with salmeterol (OR, 1.7 [CI, 1.1 to 2.7]) and formoterol (OR, 3.2 [CI, 1.7 to 6.0]) and in children (OR, 3.9 [CI, 1.7 to 8.8]) and adults (OR, 2.0 [CI, 1.1 to 3.9]). The absolute increase in hospitalization was 0.7% (CI, 0.1% to 1.3%) over 6 months. The risk for asthma-related deaths was increased (OR, 3.5 [CI, 1.3 to 9.3]), with a pooled risk difference of 0.07% (CI, 0.01% to 0.1%). LIMITATIONS: The small number of deaths limited the reliability in assessing this risk, and 28 studies did not report information on the outcomes of interest. CONCLUSIONS: Long-acting beta-agonists have been shown to increase severe and life-threatening asthma exacerbations, as well as asthma-related deaths.
Authors: Karen E Wells; Edward L Peterson; Brian K Ahmedani; Richard K Severson; Julie Gleason-Comstock; L Keoki Williams Journal: J Allergy Clin Immunol Date: 2012-01-26 Impact factor: 10.793
Authors: Shweta Choudhry; Loretta G Que; Zhonghui Yang; Limin Liu; Celeste Eng; Sung O Kim; Gunjan Kumar; Shannon Thyne; Rocio Chapela; Jose R Rodriguez-Santana; William Rodriguez-Cintron; Pedro C Avila; Jonathan S Stamler; Esteban G Burchard Journal: Pharmacogenet Genomics Date: 2010-06 Impact factor: 2.089
Authors: Steven M Swift; Mary Rose Schwarb; Kathryn A Mihlbachler; Stephen B Liggett Journal: Am J Respir Cell Mol Biol Date: 2006-09-15 Impact factor: 6.914
Authors: Long P Nguyen; Rui Lin; Sergio Parra; Ozozoma Omoluabi; Nicola A Hanania; Michael J Tuvim; Brian J Knoll; Burton F Dickey; Richard A Bond Journal: Proc Natl Acad Sci U S A Date: 2009-01-26 Impact factor: 11.205
Authors: Radhika Joshi; Daniel Valdez; Hosu Kim; Douglas C Eikenburg; Brian J Knoll; Richard A Bond Journal: Pulm Pharmacol Ther Date: 2017-07-17 Impact factor: 3.410
Authors: Victor E Ortega; Gregory A Hawkins; Stephen P Peters; Eugene R Bleecker Journal: Immunol Allergy Clin North Am Date: 2007-11 Impact factor: 3.479
Authors: Bruce J Kirenga; Jeremy I Schwartz; Corina de Jong; Thys van der Molen; Martin Okot-Nwang Journal: Afr Health Sci Date: 2015-12 Impact factor: 0.927